Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL

EyeDrops
Aldeyra hopes ongoing trials will provide data finally for FDA approval of reproxalap • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from R&D